Tyrosinase-related Protein 1 MRNA Expression in Lymph Node Metastases Predicts Overall Survival in High-risk Melanoma Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Mar 23

PMID 23519055

Citations 14

Authors

P El Hajj

F Journe

M Wiedig

I Laios

F Sales

M-D Galibert

L C van Kempen

A Spatz

B Badran

D Larsimont

A Awada

G Ghanem

Affiliations

Soon will be listed here.

Abstract

Background: Clinical outcome of high-risk melanoma patients is not reliably predicted from histopathological analyses of primary tumours and is often adjusted during disease progression. Our study aimed at extending our previous findings in skin metastases to evaluate the prognostic value of tyrosinase-related protein 1 (TYRP1) in lymph node metastases of stages III and IV melanoma patients.

Methods: TYRP1 mRNA expression in 104 lymph node metastases was quantified by real-time PCR and normalised to S100 calcium-binding protein B (S100B) mRNA expression to correct for tumour load. TYRP1/S100B ratios were calculated and median was used as cutoff value. TYRP1/S100B mRNA values were correlated to clinical follow-up and histopathological characteristics of the primary lesion.

Results: A high TYRP1/S100B mRNA ratio significantly correlated with reduced disease-free (DFS) and overall survival (OS; Cox regression analysis, P=0.005 and 0.01, respectively), increased Breslow thickness (Spearman's rho test, P<0.001) and the presence of ulceration (Mann-Whitney test, P=0.02) of the primaries. Moreover, high TYRP1/S100B was of better prognostic value (lower P-value) for OS than Breslow thickness and ulceration. Finally, it was well conserved during disease progression with respect to high/low TYRP1 groups.

Conclusion: High TYRP1/S100B mRNA expression in lymph node metastases from melanoma patients is associated with unfavourable clinical outcome. Its evaluation in lymph node metastases may refine initial prognosis for metastatic patients, may define prognosis for those with unknown or non-evaluable primary lesions and may allow different management of the two groups of patients.

Citing Articles

An -Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

Sanchez-Beltran J, Soler Diaz J, Herraiz C, Olivares C, Cerdido S, Cerezuela-Fuentes P Int J Mol Sci. 2025; 26(4).

PMID: 40004203 PMC: 11855888. DOI: 10.3390/ijms26041739.

Identification of a metabolism-linked genomic signature for prognosis and immunotherapeutic efficiency in metastatic skin cutaneous melanoma.

He Z, Lyu J, Lyu L, Long X, Xu B Medicine (Baltimore). 2024; 103(23):e38347.

PMID: 38847706 PMC: 11155616. DOI: 10.1097/MD.0000000000038347.

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.

Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A Cell. 2023; 186(7):1432-1447.e17.

PMID: 37001503 PMC: 10994488. DOI: 10.1016/j.cell.2023.03.007.

A Network of MicroRNAs and mRNAs Involved in Melanosome Maturation and Trafficking Defines the Lower Response of Pigmentable Melanoma Cells to Targeted Therapy.

Vitiello M, Mercatanti A, Podda M, Baldanzi C, Prantera A, Sarti S Cancers (Basel). 2023; 15(3).

PMID: 36765859 PMC: 9913661. DOI: 10.3390/cancers15030894.

Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.

Trilla-Fuertes L, Gamez-Pozo A, Prado-Vazquez G, Lopez-Vacas R, Zapater-Moros A, Lopez-Camacho E Int J Mol Sci. 2023; 24(1).

PMID: 36614248 PMC: 9821399. DOI: 10.3390/ijms24010801.

References

Takechi Y, Hara I, Naftzger C, Xu Y, Houghton A . A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res. 1996; 2(11):1837-42. View

Mouawad R, Spano J, Comperat E, Capron F, Khayat D . Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer. 2009; 45(8):1407-14. DOI: 10.1016/j.ejca.2008.12.015. View

Alonzo T . Standards for reporting prognostic tumor marker studies. J Clin Oncol. 2005; 23(36):9053-4. DOI: 10.1200/JCO.2005.04.3778. View

Rad H, Yamashita T, Jin H, Hirosaki K, Wakamatsu K, Ito S . Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells. Exp Cell Res. 2004; 298(2):317-28. DOI: 10.1016/j.yexcr.2004.04.045. View

Miller A, Mihm Jr M . Melanoma. N Engl J Med. 2006; 355(1):51-65. DOI: 10.1056/NEJMra052166. View

Henry L, Lavabre-Bertrand T, Douche T, Uttenweiler-Joseph S, Fabbro-Peray P, Monsarrat B . Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma. Exp Dermatol. 2010; 19(12):1054-9. DOI: 10.1111/j.1600-0625.2010.01151.x. View

Chen G, Cheng Y, Zhang Z, Martinka M, Li G . Prognostic significance of cytoplasmic p27 expression in human melanoma. Cancer Epidemiol Biomarkers Prev. 2011; 20(10):2212-21. DOI: 10.1158/1055-9965.EPI-11-0472. View

Diaz-Lagares A, Alegre E, Arroyo A, Gonzalez-Cao M, Zudaire M, Viteri S . Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011; 32(6):1155-61. DOI: 10.1007/s13277-011-0218-x. View

Kruijff S, Hoekstra H . The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012; 38(4):281-5. DOI: 10.1016/j.ejso.2011.12.005. View

10.

Patel D, Balderes P, Lahiji A, Melchior M, Ng S, Bassi R . Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies. 2008; 16(3-4):127-36. View

11.

Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco M, Chiarion-Sileni V . A gene expression signature associated with survival in metastatic melanoma. J Transl Med. 2006; 4:50. PMC: 1697826. DOI: 10.1186/1479-5876-4-50. View

12.

Balch C, Gershenwald J, Soong S, Thompson J, Ding S, Byrd D . Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010; 28(14):2452-9. PMC: 2982783. DOI: 10.1200/JCO.2009.27.1627. View

13.

Dewar D, Newell B, Green M, Topping A, Powell B, Cook M . The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004; 22(16):3345-9. DOI: 10.1200/JCO.2004.12.177. View

14.

van Houdt I, Oudejans J, van den Eertwegh A, Baars A, Vos W, Bladergroen B . Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res. 2005; 11(17):6400-7. DOI: 10.1158/1078-0432.CCR-05-0306. View

15.

Lazova R, Camp R, Klump V, Siddiqui S, Amaravadi R, M Pawelek J . Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res. 2011; 18(2):370-9. PMC: 4825867. DOI: 10.1158/1078-0432.CCR-11-1282. View

16.

Kalady M, White R, Johnson J, Tyler D, Seigler H . Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003; 238(4):528-35. PMC: 1360111. DOI: 10.1097/01.sla.0000090446.63327.40. View

17.

Hamberg A, Korse C, Bonfrer J, de Gast G . Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003; 13(1):45-9. DOI: 10.1097/00008390-200302000-00008. View

18.

Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A . On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer. 2001; 94(4):586-90. DOI: 10.1002/ijc.1504. View

19.

Liu Y, Peng Y, Mi M, Guevara-Patino J, Munn D, Fu N . Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol. 2009; 182(10):5960-9. PMC: 3077746. DOI: 10.4049/jimmunol.0900008. View

20.

Berger A, Kluger H, Li N, Kielhorn E, Halaban R, Ronai Z . Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003; 63(23):8103-7. View